Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
CNTX
CNTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest CNTX ETF News Today | Earnings, Events & Price Alerts
CNTX News
Context Therapeutics Announces Upcoming Investor Conference Schedule
Feb 09 2026
Newsfilter
Context Therapeutics Grants 120,000 Stock Options to Attract New Employees
Jan 16 2026
Globenewswire
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
Jan 06 2026
NASDAQ.COM
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
Jan 05 2026
Benzinga
BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target
Dec 22 2025
Benzinga
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
Dec 16 2025
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for Pelareorep in Colorectal Cancer
Dec 16 2025
Globenewswire
Context Therapeutics Showcases CT-95 and CT-202 Initiatives at the 2025 SITC Annual Meeting
Nov 07 2025
Newsfilter
D. Boral Capital Reiterates Buy Rating on Context Therapeutics with $9 Price Target Intact
Oct 16 2025
Benzinga
Context Therapeutics Reveals Inducement Grant in Accordance with Nasdaq Listing Rule 5635(c)(4)
Oct 03 2025
Newsfilter
Synopsys Analyst Starts Coverage with a Bearish Outlook; Check Out the Top 5 Initiations for Thursday
Oct 02 2025
Benzinga
Cantor Fitzgerald Begins Coverage of Context Therapeutics with an Overweight Rating
Oct 02 2025
Benzinga
Guggenheim Begins Coverage of Context Therapeutics (CNTX) with a Buy Rating
Sep 19 2025
NASDAQ.COM
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
Aug 07 2025
Benzinga
Piper Sandler Reiterates Overweight on Context Therapeutics, Lowers Price Target to $4
Jun 26 2025
Benzinga
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Jun 02 2025
Newsfilter
Show More News
